Related references
Note: Only part of the references are listed.Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
Laura C. Cappelli et al.
ANNALS OF THE RHEUMATIC DISEASES (2017)
Pathologically expanded peripheral T helper cell subset drives B cells in rheumatoid arthritis
Deepak A. Rao et al.
NATURE (2017)
Inflammatory cytokines compromise programmed cell death-1(PD-1)-mediated T cell suppression in inflammatory arthritis through up-regulation of soluble PD-1
D. Bommarito et al.
CLINICAL AND EXPERIMENTAL IMMUNOLOGY (2017)
Immunomodulatory Activity of Nivolumab in Metastatic Renal Cell Carcinoma
Toni K. Choueiri et al.
CLINICAL CANCER RESEARCH (2016)
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Lisa Zimmer et al.
EUROPEAN JOURNAL OF CANCER (2016)
Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial
Jonathan E. Rosenberg et al.
LANCET (2016)
Psoriasis and psoriatic arthritis induced by nivolumab in a patient with advanced lung cancer
Sarah Law-Ping-Man et al.
RHEUMATOLOGY (2016)
Arthritis and Tenosynovitis Associated With the Anti-PD1 Antibody Pembrolizumab in Metastatic Melanoma
Matthew M. K. Chan et al.
JOURNAL OF IMMUNOTHERAPY (2015)
Ipilimumab-induced colitis in patients with metastatic melanoma
Kara M. De Felice et al.
MELANOMA RESEARCH (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
The future of immune checkpoint therapy
Padmanee Sharma et al.
SCIENCE (2015)
Soluble PD-1 aggravates progression of collagen-induced arthritis through Th1 and Th17 pathways
Cuiping Liu et al.
ARTHRITIS RESEARCH & THERAPY (2015)
The PD-1/PD-Ls pathway and autoimmune diseases
Suya Dai et al.
CELLULAR IMMUNOLOGY (2014)
Increased soluble programmed death-1 (sPD-1) is associated with disease activity and radiographic progression in early rheumatoid arthritis
S. R. Greisen et al.
SCANDINAVIAN JOURNAL OF RHEUMATOLOGY (2014)
Synovial T cell hyporesponsiveness to myeloid dendritic cells is reversed by preventing PD-1/PD-L1 interactions
Frederique M. Moret et al.
ARTHRITIS RESEARCH & THERAPY (2014)
GSVA: gene set variation analysis for microarray and RNA-Seq data
Sonja Haenzelmann et al.
BMC BIOINFORMATICS (2013)
New learnings on the pathophysiology of RA from synovial biopsies
Costantino Pitzalis et al.
CURRENT OPINION IN RHEUMATOLOGY (2013)
Abatacept: A Review of its Use in the Management of Rheumatoid Arthritis
Gillian M. Keating
DRUGS (2013)
In Vivo Blockade of the Programmed Cell Death-1 Pathway Using Soluble Recombinant PD-1-Fc Enhances CD4+ and CD8+ T Cell Responses but Has Limited Clinical Benefit
Praveen K. Amancha et al.
JOURNAL OF IMMUNOLOGY (2013)
Adenovirus Expressing Both Thymidine Kinase and Soluble PD1 Enhances Antitumor Immunity by Strengthening CD8 T-cell Response
Seung-Pil Shin et al.
MOLECULAR THERAPY (2013)
Safety and Tumor Responses with Lambrolizumab (Anti-PD-1) in Melanoma
Omid Hamid et al.
NEW ENGLAND JOURNAL OF MEDICINE (2013)
Learning about the natural history of rheumatoid arthritis development through prospective study of subjects at high risk of rheumatoid arthritis-related autoimmunity
Kevin D. Deane
ARTHRITIS AND RHEUMATISM (2012)
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
F. Stephen Hodi et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Soluble PD-1 is Associated with Aberrant Regulation of T Cells Activation in Aplastic Anemia
Haijing Wu et al.
IMMUNOLOGICAL INVESTIGATIONS (2009)
Soluble PD-1 rescues the proliferative response of simian immunodeficiency virus-specific CD4 and CD8 T cells during chronic infection
Nattawat Onlamoon et al.
IMMUNOLOGY (2008)
Therapeutic T-cell manipulation in rheumatoid arthritis: past, present and future
J. D. Isaacs
RHEUMATOLOGY (2008)
Aberrant regulation of synovial T cell activation by soluble costimulatory molecules in rheumatois arthritis
Bing Wan et al.
JOURNAL OF IMMUNOLOGY (2006)
Establishment of NOD-Pdcd1-/- mice as an efficient animal model of type I diabetes
J Wang et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2005)
Co-inhibitory molecules of the B7-CD28 family in the control of T-cell immunity
LP Chen
NATURE REVIEWS IMMUNOLOGY (2004)
Autoimmune dilated cardiomyopathy in PD-1 receptor-deficient mice
H Nishimura et al.
SCIENCE (2001)
Engagement of the PD-1 immunoinhibitory receptor by a novel B7 family member leads to negative regulation of lymphocyte activation
GJ Freeman et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2000)